Requires that health insurance policies shall provide coverage for follow-up screening or diagnostic services for lung cancer; provides that no patient cost sharing shall be imposed for follow-up screening or diagnostic services for lung cancer.
S02000 would require most New York health insurance policies that provide medical, major medical, or similar comprehensive coverage to cover follow-up screening or diagnostic services for lung cancer when recommended by a health care provider and consistent with nationally recognized clinical practice guidelines. The bill applies this mandate across individual, group, and nonprofit health insurance policies, and it defines the guidelines standard as evidence-based, peer-reviewed guidance developed through transparent processes by independent organizations or medical professional societies.
The bill also prohibits patient cost sharing for these follow-up screening or diagnostic services, meaning insurers could not impose copays, coinsurance, or similar out-of-pocket charges for the covered services. It preserves insurer medical management tools, including utilization review and prior authorization, so long as those controls are used to ensure consistency with the applicable clinical guidelines. For high-deductible health plans, the bill allows the coverage to remain subject to the deductible if necessary to preserve eligibility for a health savings account. The act would take effect January 1, 2027, and would apply to policies and contracts issued, renewed, modified, altered, or amended on or after that date.
The bill would amend sections 3216, 3221, and 4303 of the New York Insurance Law to create a new mandatory benefit for lung cancer follow-up screening and diagnostic services. Its practical effect would be to expand required insurance coverage and eliminate patient cost sharing for these services in most comprehensive health plans, while still allowing insurers to apply utilization review and, in some cases, deductibles for high-deductible health plans. The mandate would affect individual, group, and nonprofit insurers and would apply prospectively to policies updated on or after the effective date.
The available voting history shows strong and unanimous support for the bill. It passed the Senate Insurance Committee 11-0 and later passed the Senate floor 61-0, with a subsequent floor passage recorded 56-0. The absence of recorded opposition suggests broad bipartisan agreement around improving access to lung cancer follow-up care and reducing financial barriers to diagnosis and screening.
There is little evidence of substantive opposition in the provided record, but the bill does preserve some insurer controls that could be points of discussion. Insurers may continue medical management and prior authorization, which could raise concerns among patient advocates about administrative barriers even though the services must align with recognized guidelines. Another potential issue is the high-deductible health plan exception, which allows deductibles to apply when needed to preserve HSA eligibility; that carve-out may limit the practical no-cost coverage for some enrollees. Overall, however, the bill appears to have been noncontroversial in committee and on the floor.